CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.

2026

8 Jul 2026, 11:30
Hansa Biopharma to host Q2 2026 interim results conference call
2 Jul 2026, 13:00
Hansa Biopharma participating in Wedbush PacGrow Renal Summit
1 Jul 2026, 14:30 | Regulatory
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

· SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
· The transaction significantly strengthens Hansa’s financial position and enables a robust US launch, subject to US approval of imlifidase
24 Jun 2026, 22:40
Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for ‘What’s Hot, What’s New’ Plenary at ATC 2026
15 Jun 2026, 07:00
Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer
12 Jun 2026, 07:00
Hansa Biopharma invite to Capital Markets Day 2026 in New York
10 Jun 2026, 08:00
Hansa Biopharma appoints Fredrik Röök as VP Business Development
2 Jun 2026, 12:35
Hansa Biopharma participating in Jefferies Global Healthcare Conference in New York
Load more

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.